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Background—Brain natriuretic peptide (BNP) is a marker of ventricular dysfunction and can be used to assess prognosis
in heart failure and after myocardial infarction. Heart involvement is the most important prognostic factor and causes
death in almost all patients with light-chain amyloidosis (AL). We investigated the prognostic value of NT-proBNP and
its utility in monitoring amyloid heart dysfunction.
Methods and Results—NT-proBNP was quantified at diagnosis in 152 consecutive patients seen at the coordinating center
of the Italian Amyloidosis Study Group (Pavia) from 1999 throughout 2001. Heart involvement was estimated on the
basis of clinical signs, electrocardiography, and echocardiography. NT-proBNP concentrations differed in patients with
(n90, 59%) and without (n62, 41%) heart involvement (median: 507.8 pmol/L versus 22.1 pmol/L, P107). The
best cutoff for heart involvement was at 152 pmol/L (sensitivity: 93.33%, specificity: 90.16%, accuracy: 92.05%) and
distinguished two groups with different survival (P0.001). The Cox multivariate model including NT-proBNP was
better than models including echocardiographic and clinical signs of heart involvement. NT-proBNP appeared to be
more sensitive than conventional echocardiographic parameters in detecting clinical improvement or worsening of
amyloid cardiomyopathy during follow-up.
Conclusions—NT-proBNP appeared to be the most sensitive index of myocardial dysfunction and the most powerful
prognostic determinant in AL amyloidosis. It adds prognostic information for newly diagnosed patients and can be
useful in designing therapeutic strategies and monitoring response. NT-proBNP is a sensitive marker of heart toxicity
caused by amyloidogenic light chains. (Circulation. 2003;107:2440-2445.)
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Amyloidoses are disorders of protein conformation andmetabolism that result in tissue deposition of insoluble
fibrils, organ dysfunction, and death. In primary systemic
amyloidosis (AL), fibrils are composed mostly by the
N-terminus of a monoclonal immunoglobulin light chain.1
AL is a systemic disease, and most patients have clinical
involvement of more than one organ at diagnosis. Half of
patients present with various degrees of cardiac amyloidosis
at diagnosis, but virtually all eventually die of cardiac-related
death.2 Heart involvement is by far the major prognostic
determinant3 and conditions the therapeutic strategy.
No biochemical marker is presently available for the
diagnosis of amyloid heart involvement and the monitoring of
cardiac function after therapy. Currently used tools, such as
low voltages on ECG, increased interventricular septum
(IVS) thickness and “granular sparkling” at echocardiogra-
phy, have unsatisfactory sensitivity and/or specificity.2
Natriuretic peptides, particularly brain (or type B) natri-
uretic peptide (BNP), have been reported to be very effective
in diagnosing ventricular dysfunction4 and in assessing prog-
nosis of heart failure and after myocardial infarction.5
Takemura and colleagues6 demonstrated that the expression
of atrial natriuretic peptide (ANP) and BNP was augmented
in the ventricular myocytes of patients with cardiac amyloid-
osis, particularly in regions adjacent to amyloid deposits, and
showed that the elevation of BNP was more pronounced than
that of ANP.
BNP is initially formed as a prepro-polypeptide that
undergoes consecutive proteolytic cleavage steps to produce
the active hormone (amino acids 77 to 108) and the
N-terminal inactive peptide (NT-proBNP) (amino acids 1 to
76) on release. The N-terminal peptide and the hormone are
secreted on an equimolar basis.7,8 We evaluated the level of
NT-proBNP as a marker of cardiac involvement in a consec-
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utive series of 152 patients with AL amyloidosis and assessed
its prognostic value.
Methods
Patient Evaluation
NT-proBNP was evaluated at diagnosis in all patients with AL
amyloidosis seen between January 1999 and December 2001 at the
coordinating center of the Italian Amyloidosis Study Group (Internal
Medicine and Medical Oncology, Pavia, Italy). All patients had
biopsy-proven amyloidosis in association with a clonal plasma cell
disorder. Patients on dialysis were excluded because of altered
metabolism of NT-proBNP.9
Patients gave consent for the use of their blood samples for
experimental purposes, in accordance with Institutional Review
Board guidelines.
To define heart involvement, the investigators, who were blind to
the NT-proBNP results, relied on the presence of at least one of the
following criteria: clinical symptoms of heart failure (severity of
symptoms was graded according to the New York Heart Association
classification class II), unexplained low voltages on the resting
ECG (ie, QRS voltage amplitude in the limb leads 0.5 mV, in the
absence of pericardial effusion or myxedema), and at least one of the
following echocardiographic features: increased IVS thickness in
the absence of hypertension, valvular disease or ECG criteria for left
ventricular hypertrophy and/or increased myocardial echogenicity
(granular sparkling), and/or unexplained increased right ventricular
free wall and/or unexplained increased posterior wall.2 In our
laboratory, the intraobserver and interobserver coefficient of varia-
tion of the measurements are, respectively, 3.2% and 3.9% for septal
wall thickness and 3.4% and 3.9% for posterior wall thickness.
Reference limits were 12 mm for IVS thickness, 7 mm for the
right ventricular free wall, and 12 mm for the posterior wall. The
ejection fraction was evaluated by the standard 2-dimensional
area-length method in the 4-chamber echocardiographic view.
Follow-up visits were scheduled every 3 months. Urine and blood
samples were collected for immunofixation and determination of
serum creatinine and proteinuria, using routine laboratory methods.
Serum and urine monoclonal proteins were detected by high-
resolution immunofixation10 and quantified according to the guide-
lines of the College of American Pathologists.11
Hematological response to treatment was defined as a 50%
decrease in serum and urine monoclonal component.12 The response
was evaluated every 3 months and established at the nadir of serum
and urine monoclonal protein.
Serum NT-proBNP Quantification
Serum samples were frozen immediately and kept at 20°C until
NT-proBNP testing. NT-proBNP levels were measured with an
electrochemiluminescence sandwich immunoassay (ECLIA, Roche)
on an Elecsys System 2010. Serum NT-proBNP levels are typically
higher in women and increase with age, therefore upper reference
limits (the 97.5 percentiles of healthy subjects) in men and women
are, respectively, 10.4 pmol/L and 18 pmol/L in subjects 50 years
old; and 26.4 pmol/L and 39.8 pmol/L in individuals 50 years old
(data generated by Roche from 712 normal subjects). Within-run
precision was determined to be 3.5% at 23.9 pmol/L (22 samples)
and 2.6% at 1318 pmol/L (22 samples); between-run precision was
3.9% at 25 pmol/L (22 samples) and 3.1% at 1403.3 pmol/L (22
samples). The detection limit reported by the manufacturer is 0.6
pmol/L.
Statistical Analysis
Differences in mean NT-proBNP concentrations between subgroups
were tested for statistical significance by the nonparametric Mann-
Whitney U test, because NT-proBNP was not normally distributed.
Receiver operator characteristic (ROC) analysis was performed to
determine the best cutoff values to detect cardiac involvement,
defined as reported above, as well as to assess the discrimination
ability (by calculating the area under the ROC curve) of NT-proBNP
to recognize patients with heart involvement. A “heart involvement
score” accounting for relevant echocardiographic (IVS thickness
12 mm and ejection fraction 50%) and clinical features (NYHA
class II) was computed on the basis of the presence of 0, 1, 2, or
3 of such features. Cumulative survival probability from diagnosis
was calculated by means of the Kaplan-Meier estimator. To identify
possible predictors of survival, a series of univariate Cox models
were fitted. Subgroup analysis was performed to assess survival from
time of response separately in patients with NT-proBNP below and
above the cutoff value. Variables with probability values of 0.2
were introduced into multivariate Cox models. Model validation was
performed by calculating Maddala-explained variation and LeCessie–
van Houwelingen shrinkage coefficient for calibration. Discrimina-
tion was assessed graphically by calculating the linear predictor
according to the Cox model and plotting Kaplan-Meier curves of the
quartiles of its distribution. In patients with NT-proBNP above the
cutoff value, NT-proBNP levels before and after treatment were
compared by means of the Wilcoxon matched pairs test.
Results
Patient Characteristics and Outcome
One hundred fifty-two patients with AL were included in the
study, and their main characteristics are reported in Table 1.
TABLE 1. Main Characteristics of the Studied AL Population
No. of patients 152
Age, median (range) 61 (34–78)
Monoclonal protein in serum or urine 149 (98)
Serum /, biclonal 106/31 (71/21), 12 (8)
Urine /, biclonal 109/33 (73/22), 7 (5)
Amyloid organ involvement
Single/2 or more 54/98 (36/64)
Dominant syndrome
Kidney 59 (39)
Heart 58 (38)
Liver 11 (7)
Peripheral nervous system 6 (4)
Soft tissues 3 (2)
Skin 3 (2)
Lymph nodes 3 (2)
Lung 3 (2)
Other 6 (4)
Clinical evidence of kidney involvement 94 (62)
Nephrotic syndrome 47 (31)
Serum creatinine 106.1 mol/L (1.2 mg/dL) 24 (16)
Clinical evidence of heart involvement 90 (59)
Heart failure (NYHA class II) 58 (38)
IVS thickness 15 mm 43 (29)
Ejection fraction 50% 35 (23)
Treatment for 6 mo 116 (76)
Oral melphalan plus prednisone 54
High-dose dexamethasone 34
Autologous stem cell transplantation 19
Various (thalidomide, iododoxorubicin,
immunotherapy, other alkylating agents)
9
Values are n (%) or median (range).
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Median age was 61 years, with only 17% of patients 50
years old.
A monoclonal component was found by high-resolution
immunofixation in the serum and/or urine of 149 (98%)
patients. In the remaining 3 patients, the diagnosis was
confirmed by immunoelectronmicroscopy.13 There was a
clear predominance of  over  light chains both in serum and
urine.
In 98 (64%) patients, more than one organ was involved at
diagnosis. Evidence of heart involvement was found in 90
(59%), and heart failure (NYHA class II) was the dominant
clinical feature in 58 (38%). Forty-three patients (29%) had
an IVS thickness 15 mm, and 35 (23%) had an ejection
fraction 50%.
One-hundred 16 patients were treated with chemotherapy
for 6 months or more, as reported in Table 1.
The median overall follow-up was 12 months (range, 0.3 to
44.8), 17 (range, 3 to 44) for living patients and 3.5 (range,
0.3 to 44.8) for those who had died. The cause of death was
cardiac in 38 (79%) of the 48 patients in whom it was known:
26 patients died of heart failure and 12 of sudden death.
NT-proBNP and Amyloid Heart Involvement
Median NT-proBNP in patients with heart involvement was
507.8 pmol/L (range, 54.5 to 4130 pmol/L) and in the 35
patients with ejection fraction 50% it was 940.1 pmol/L
(range, 167 to 4130 pmol/L). Remarkably, in no case was
NT-proBNP lower than the 97.5 percentile for normal sub-
jects, indicating 100% sensitivity. By contrast, patients with-
out apparent cardiac amyloidosis had significantly (P107)
lower NT-proBNP levels (median, 22.1 pmol/L; range, 1.1 to
1175 pmol/L), although there was an overlap with the other
group (Figure 1). Because the distribution of NT-proBNP
levels within the population was skewed, the logarithm (ln) of
its value was used for statistical analysis.
The area under the ROC curve for the detection of heart
involvement was high: 0.96 (95% CI, 0.92 to 0.99) (Figure 2).
The best cutoff for the diagnosis of heart involvement was
152 pmol/L. With this cutoff, sensitivity was 93.33%, spec-
ificity was 90.16%, and accuracy was 92.05%. Using the
prevalence (59%) of heart involvement observed in our
cohort, the positive and negative predictive values were
93.33% and 90.32%, respectively. Eight patients with normal
echocardiograms had NT-proBNP above the cutoff value.
However, 4 had clinical signs of heart failure (exertional
dyspnea and peripheral edema in all cases plus hepatomegaly
in 2 patients), therefore being classified as patients with
amyloid heart involvement. The cutoff discriminated two
groups with highly significant survival difference: 9 months
versus not reached (P0.0001) (Figure 3).
Prognostic Relevance of NT-proBNP
The death rate for patients with NT-proBNP level below and
above 152 pmol/L was 7.6 per 100 person-years (95% CI, 3.6
to 15.7) and 72.2 per 100 person-years (95% CI, 54.2 to 86.1),
respectively. The Cox univariate model is reported in Table 2.
It includes, in addition to the single variables, also the “heart
involvement score” as defined in the Methods section. Be-
cause ln(NT-proBNP), evidence of heart involvement, the
score, IVS thickness, and NT-proBNP cutoff (152 pmol/L)
were correlated to each other, 5 competitive Cox multivariate
models were generated. The model including ln(NT-proBNP)
(Table 2) had the highest prognostic power, according to
model validation statistics, even in respect to the model
including the “heart involvement score” (data not shown).
Response to treatment resulted in survival benefit both in
the group of patients with NT-proBNP level above the cutoff
value (P0.0002) (Figure 4A) and in patients with NT-
proBNP level below the cutoff value (P0.02) (Figure 4B).
Interestingly, none of the patients with NT-proBNP below the
cutoff value died after the achievement of hematological
response.
Four patients with NT-proBNP serum concentrations
above the cutoff value did not have amyloid heart involve-
ment. Their characteristics are reported in Table 3. Two of
them, with high serum creatinine, probably had subclinical
heart involvement that was not detectable by means of
conventional echocardiography and clinical evaluation: One
of them died suddenly 6 months later and the other died of
heart failure 11 months later. The two remaining patients do
not have renal failure or evidence of heart involvement 12 and
10 months after diagnosis, and at present we do not have a
plausible explanation for this discrepancy.
Figure 1. Level of NT-proBNP in patients with AL amyloidosis.
Figure 2. ROC curve based on ln(NT-proBNP). Area under the
curve: 0.9561 (95% CI, 0.9209 to 0.9913).
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Monitoring the Response to Therapy With
NT-proBNP
Variations in NT-proBNP concentration were monitored in
41 patients with a long follow-up. Of these, 21 had a
concentration above the cutoff at diagnosis and achieved a
hematological response. Among these 21 patients, the reduc-
tion of the amyloidogenic protein 50% was accompanied
by a significant reduction of NT-proBNP (median, 402.5
pmol/L versus 165.8 pmol/L; P0.0001) in 19 patients
(90.5%), whereas the echocardiographic parameters im-
proved (3 mm reduction of IVS thickness in all cases and of
left ventricular posterior wall in 3 and normalization of
ejection fraction in the two patients in whom it was reduced)
only in 6 (28.6%) patients. In 9 of the 21 patients, the
NT-proBNP dropped below 152 pmol/L. Of the 2 cases
without NT-proBNP reduction, 1 had refractory congestive
heart failure and died 4 weeks later and the other died of heart
failure after 29 months. The modifications of NT-proBNP
were closely related to clinical heart manifestations and
Figure 3. Survival of patients with AL
amyloidosis according to NT-proBNP
cutoff value (152 pmol/L).
TABLE 2. Cox Survival Analysis
Variable
Hazard
Ratio 95% CI P
Univariate model
Male gender 2.25 1.16–4.37 0.010
Age (y) 1.02 1.00–1.05 0.087
ln(NT-proBNP) (pmol/L) 1.68 1.40–2.00 0.001
NT-proBNP (152 pmol/L) 6.80 3.05–15.17 0.001
Heart involvement (clinical evidence) 7.21 3.24–16.06 0.001
IVS thickness (mm) 1.14 1.06–1.23 0.001
NYHA class II 4.28 2.42–7.59 0.001
Heart involvement score 1.81 1.43–2.3 0.001
No. of organs involved 1.76 1.38–2.26 0.001
Weight loss (kg/mo) 2.17 1.27–3.85 0.005
ln(creatinine) (mol/L) 1.48 0.99–2.22 0.072
Multivariate model
ln(NT-proBNP) (pmol/L) 1.62 1.33–1.98 0.001
Male gender 1.93 0.99–3.76 0.054
Age (y) 1.01 0.97–1.04 0.718
Weight loss (kg/mo) 1.56 0.87–2.79 0.137
ln(creatinine) (mol/L) 0.85 0.54–1.36 0.508
Figure 4. Effect of response to therapy on survival: A, Patients
with NT-proBNP 152 pmol/L; B, patients with NT-proBNP
152 pmol/L. Hematologic response to treatment was defined
as 50% decrease in serum and urine monoclonal component.
Palladini et al NT-proBNP Predicts Survival in AL Amyloidosis 2443
response to therapy. This report gives detailed data of two
representative cases.
Patient 1 (Figure 5A) was a 60-year-old woman, diagnosed
in July 1998 with multiple myeloma and cardiac amyloidosis
(IVS thickness, 14 mm; NYHA class IV). She achieved a
hematological response after 8 courses of high-dose dexa-
methasone with marked improvement of heart dysfunction
(NYHA class from IV to II). She relapsed in January 2001
with an increase of monoclonal component and eventually
died of heart failure in October 2001. NT-proBNP level
paralleled the initial decrease of the serum monoclonal
component (NT-proBNP, from 1138 to 423 pmol/L; mono-
clonal component, from 25 to 6 g/L) and its subsequent
progression (NT-proBNP, 1663 pmol/L; monoclonal compo-
nent, 48 g/L at the time of patient’s death). However, the IVS
thickness did not change significantly throughout the course
of the disease until the last observation 1 month before the
patient’s death (15 mm).
Patient 2 (Figure 5B) is a 40-year-old man, diagnosed with
cardiac amyloidosis in May 1997. He had exertional dyspnea
and ventricular arrhythmias (IVS thickness, 20 mm; NYHA
class III). He achieved a complete hematological remission
after two autologous stem cell transplantations, with improve-
ment of heart function and return to full working activity.
NT-proBNP dropped immediately after treatment (from 249
to 89 pmol/L) and is now within the reference range (25.8
pmol/L), whereas IVS thickness, after an initial increase (up
to 22 mm), remained stable (18 to 17 mm) throughout the
follow-up.
The parallelism between monoclonal component concen-
tration and NT-proBNP observed in the majority of patients
suggests a cause-effect relation.
Discussion
No biochemical marker is presently available for assessing
prognosis and monitoring the effect of therapy on amyloid
cardiac dysfunction. The results obtained in this cohort of
patients show that (1) NT-proBNP is a sensitive marker of
heart dysfunction in amyloid patients, (2) it is the most
powerful prognostic factor in AL; (3) increased NT-proBNP
levels can detect inapparent heart involvement; and (4)
NT-proBNP is useful in monitoring heart dysfunction caused
by the amyloidogenic light chains and response to therapy.
NT-proBNP in Diagnosing Amyloid Heart
Dysfunction and in Defining Prognosis
The diagnosis of amyloid heart involvement relies on evi-
dence from ECGs, echocardiograms, clinical examination,
and the patient’s history. The judgment of this evidence
requires experienced physicians and is expensive. Moreover,
interoperator variability might affect the evaluation of
follow-up echocardiograms. The sensitivity (93.33%) and
specificity (90.16%) of NT-proBNP quantification are supe-
rior to those achievable by measurement of IVS thickness or
by the detection of granular sparkling of myocardial texture at
echocardiography.2 Very recently, Koyama and coworkers14
showed that the quantification of cycle-dependent variations
of myocardial integrated backscatter may at least in part
overcome the limitation of the somewhat subjective evalua-
tion of indexes of increased myocardial echogenicity. How-
ever, the availability of this analysis is presently very limited.
Our group reported that 99mTc-aprotinin scintigraphy has both
high sensitivity (95%) and specificity (97%) in detecting
TABLE 3. Patients Without Clinical Evidence of Heart Involvement and With NT-proBNP >152 pmol/L
Patient Gender
Age,
y
Organs
Involved
NT-proBNP,
pmol/L
IVS
Thickness,
mm
Ejection
Fraction,
%
Creatinine,
mol/L Follow-Up
1 M 62 Kidney 1175.0 11 51 442.0 Sudden death at 6 mo
2 F 67 Kidney 351.3 10 68 238.7 Heart failure and death at 11 mo
3 M 71 Liver 402.5 10 73 75.1 Alive at 12 mo
4 F 66 Kidney 160.9 9 56 68.9 Alive at 10 mo
M indicates male; F, female.
Figure 5. A, Patient 1; B, patient 2. IVS indicates interventricular
septum; sMC, serum monoclonal component; NYHA, New York
Heart Association; ASCT, autologous stem cell transplantation.
See text for patients’ clinical history.
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cardiac amyloidosis15 but scintigraphy is cumbersome, ex-
pensive, and not readily available.
NT-proBNP measurement is widely available, extremely
robust with an excellent reproducibility, and it is less expen-
sive than echocardiography. As cardiac involvement is an
adverse factor for autologous stem cell transplantation,16 the
value of this marker has potential for deciding the initiation of
chemotherapy and designing optimal treatment.
According to our data, NT-proBNP is the most powerful
tool in prognostic assessment of patients with AL. The
multivariate model including ln(NT-proBNP) could discrim-
inate prognostic groups better than the models including IVS
thickness, or clinical judgment of heart involvement, or even
a score accounting for relevant echocardiographic and clini-
cal evidence of heart involvement. Its extremely wide dy-
namic range (from 1.1 to 4130 pmol/L) observed in our
patient population and excellent reproducibility make NT-
proBNP quantification a useful marker for monitoring the
effect of treatment on heart involvement. The availability of
this biochemical marker should also ease the comparison
between the outcomes of different populations of patients
with amyloidosis.
NT-proBNP in Follow-Up and Monitoring
Response to Therapy
In our study, we observed a tight time correlation between
clinical status, modification of monoclonal component, and
NT-proBNP level during follow-up. The hematologic re-
sponse to certain chemotherapy regimens can be achieved in
a relatively short period of time; this is not, however, always
reflected in the echocardiography pattern, which improves
slowly, if ever. In fact, in 90% of patients with NT-proBNP
value above the cutoff who achieved hematologic response,
the NT-proBNP level markedly decreased, whereas echocar-
diographic findings did not significantly alter in 71% of them.
This indicates that monitoring NT-proBNP significantly con-
tributes to better estimate the effect of therapy.
In addition, these findings provide clues to the pathogen-
esis of the disease: The NT-proBNP increase in many of the
AL amyloidosis patients before treatment may actually reflect
the cardiotoxicity of the amyloidogenic light chains. This is
concordant with the observation that patients with amyloid-
osis caused by transthyretin (who do not have pathogenic
circulating light chains) may have severe myocardial infiltra-
tion but minimal heart failure17 and with the observation that
the infusion of light chains from patients with cardiac
amyloidosis rapidly causes diastolic dysfunction in isolated
mouse hearts.18 Thus, heart dysfunction in amyloidosis might
not only depend on the extent of amyloid deposition but could
be partly related to a toxic effect of amyloidogenic light
chains (oligomers?) exerted directly on myocardial cells. This
underlines the importance of achieving the disappearance of
the monoclonal component with therapies directed against the
amyloidogenic plasma cell clone. Our data indicate that
NT-proBNP measurement represents a novel powerful tool
for assessing the prognosis of patients with AL, for designing
optimal treatment and for evaluating response to treatment.
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